Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alector, Inc.
  6. Summary
    ALEC   US0144421072

ALECTOR, INC.

(ALEC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
24.26(c) 25.46(c) 26.81(c) 25.77(c) 26.17(c) Last
519 941 461 938 1 410 851 748 940 527 352 Volume
+2.10% +4.95% +5.30% -3.88% +1.55% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 262 M - -
Net income 2021 57,1 M - -
Net cash position 2021 137 M - -
P/E ratio 2021 36,9x
Yield 2021 -
Sales 2022 227 M - -
Net income 2022 -66,8 M - -
Net cash position 2022 104 M - -
P/E ratio 2022 -34,8x
Yield 2022 -
Capitalization 2 117 M 2 117 M -
EV / Sales 2021 7,56x
EV / Sales 2022 8,87x
Nbr of Employees 184
Free-Float 87,0%
More Financials
Company
Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy... 
More about the company
Ratings of Alector, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ALECTOR, INC.
09/09ALECTOR : First Patient Dosed in Mid-Stage Study of Alector, GlaxoSmithKline's AL001 to Tr..
MT
09/09ALECTOR : Announces First Participant Dosed in Phase 2 Study Evaluating AL001 in Amyotroph..
AQ
09/09Alector Announces First Participant Dosed in Phase 2 Study Evaluating Al001 in Amyotrop..
CI
09/08ALECTOR, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/08Alector, Inc. Announces Executive Changes
CI
09/08Alector, Inc. Announces Executive Changes
CI
09/08Health Care Stocks Edging Lower Just Ahead of Wednesday Close
MT
09/08ALECTOR : COO, Chief Medical Officer Stepping Down -- Shares Drop in Pre-Market Trading
MT
09/07ALECTOR : COO, Chief Medical Officer Stepping Down
MT
09/07ALECTOR : Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President ..
PU
09/07ALECTOR, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibi..
AQ
09/07ALECTOR : Provides Executive Leadership Update
AQ
09/07Alector, Inc. Announces Executive Changes
CI
09/02ALECTOR : to Present at Upcoming Virtual Healthcare Conferences
AQ
08/03ALECTOR : Announced global collaboration with GSK to co-develop and co-commercialize progr..
PU
More news
News in other languages on ALECTOR, INC.
09/09Le premier patient reçoit une dose dans le cadre de l'étude de mi-parcours d'Alector, l..
09/08Les actions du secteur de la santé en baisse juste avant la clôture de mercredi
09/07Le directeur de l'exploitation et le directeur médical d'Alector quittent leurs fonctio..
07/09PUMP / DUMP #19 : Les Tops & Flops de la semaine
07/02DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 02.07.2021 - 15.15 Uhr
More news
Analyst Recommendations on ALECTOR, INC.
More recommendations
Chart ALECTOR, INC.
Duration : Period :
Alector, Inc. Technical Analysis Chart | ALEC | US0144421072 | MarketScreener
Technical analysis trends ALECTOR, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 26,17 $
Average target price 44,00 $
Spread / Average Target 68,1%
EPS Revisions
Managers and Directors
Arnon Rosenthal Chief Executive Officer & Director
Shehnaaz Suliman President, Chief Operating & Business Officer
Linda M. Rubinstein Chief Financial & Accounting Officer
Tillman U. Gerngross Chairman
Robert Paul Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ALECTOR, INC.72.97%2 117
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.35.75%69 407
REGENERON PHARMACEUTICALS33.91%67 262
VERTEX PHARMACEUTICALS-21.38%48 202